Midodrine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Midodrine: From Orthostatic Hypotension to Broader Hypotensive Disorder Management
One-Sentence Summary
Midodrine is an established peripheral alpha-1 adrenergic agonist used internationally for neurogenic orthostatic hypotension. The evidence pack’s top TxGNN-ranked predictions (prion disease, faciodigitogenital syndrome, ADHD, monogenic obesity, developmental disorder, hypertelorism, sinoatrial disorders) are explicitly flagged by the pack’s own rationale notes as high-score false positives with no mechanistic or clinical support, so this report instead evaluates the one candidate with substantive evidence: Hypotensive Disorder, a broader category covering dialysis-associated, perioperative, spinal-cord-injury (SCI)-associated, and heart-failure-associated hypotension, supported by 9 clinical trials and 19 publications.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this market’s regulatory data (drug not locally marketed); internationally established for (neurogenic) orthostatic hypotension |
| Predicted New Indication | Hypotensive Disorder |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L2 |
| Market Status | Not Marketed |
| Number of Licenses | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
original_moa is flagged as a data gap in this evidence pack. However, literature within the pack itself (McTavish & Goa, 1989, PMID 2480881) describes midodrine as a peripheral alpha-adrenergic agonist whose active metabolite, desglymidodrine, raises standing blood pressure through vasoconstriction. This is independently corroborated by the pack’s own rationale notes on the discarded predictions (e.g., “midodrine 本身無中樞作用，僅為周邊 alpha-1 促效劑”), which consistently describe it as a peripherally-restricted, non-CNS-penetrant vasopressor.
“Hypotensive disorder” is not a mechanistically novel target — it is the broader disease category that midodrine’s established pharmacology already addresses. The clinical trial evidence shows the model correctly recovering related, more specific hypotensive syndromes: intradialytic hypotension in critically ill AKI patients, orthostatic hypotension after spinal-cord injury, post-spinal-anesthesia hypotension in hip arthroplasty, and hypotension in HFrEF. Because these all share the same vasoconstrictive mechanism as midodrine’s known indication, the prediction reads as a mechanistically coherent extension rather than a speculative new use — unlike the other nine ranked candidates in this pack, which have no plausible pharmacological link and are explicitly labeled as noise.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03431194 | NA | Completed | 80 | Randomized trial of oral midodrine for intradialytic hypotension in critically ill AKI patients |
| NCT05548985 | NA | Completed | 58 | RCT of oral midodrine for prophylaxis against post-spinal-anesthesia hypotension in elderly hip arthroplasty patients |
| NCT02307565 | Phase 3 | Completed | 19 | Midodrine-driven BP elevation improves cerebral blood flow and cognition in SCI |
| NCT02893553 | Phase 2 | Completed | 21 | Normalizing BP improves cerebral blood flow in chronic hypotensive SCI patients |
| NCT03037879 | NA | Completed | 10 | 30-day midodrine-driven BP elevation to treat cognitive deficits in SCI |
| NCT01030874 | NA | Completed | 356 | Multidisciplinary intervention for orthostatic hypotension in rehabilitation unit patients |
| NCT02307526 | Phase 2 | Completed | 10 | Acetylcholinesterase inhibition as an alternative approach to orthostatic hypotension in SCI (comparator context, not midodrine itself) |
| NCT06405555 | Phase 2/3 | Not yet recruiting | 56 | Pilot open-label RCT of midodrine for hypotension in HFrEF |
| NCT05839652 | Phase 4 | Recruiting | 25 | Pharmacological and non-pharmacological treatment of orthostatic hypotension in SCI |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 25644760 | 2015 | RCT | Hepatology | Randomized trial: midodrine + octreotide + albumin vs. terlipressin + albumin for hepatorenal syndrome |
| 39619823 | 2024 | RCT | Topics in Spinal Cord Injury Rehabilitation | 30-day midodrine vs. placebo on BP, cerebral blood flow, and cognition in SCI |
| 2480881 | 1989 | Review | Drugs | Foundational review of midodrine pharmacology and use in orthostatic and secondary hypotension |
| 38205630 | 2024 | Guideline | Hypertension | AHA scientific statement on orthostatic hypotension in adults with hypertension |
| 38123372 | 2024 | Expert Position Statement | Revue Neurologique | Review and expert consensus on orthostatic hypotension management |
| 28050656 | 2017 | Consensus Panel | Journal of Neurology | Consensus recommendations for screening, diagnosis, and treatment of neurogenic OH |
| 31996627 | 2020 | Review | Continuum (Minneapolis, Minn.) | Management of orthostatic hypotension, emphasis on neurogenic OH |
| 35029940 | 2022 | Review | American Family Physician | Practical diagnostic and treatment approach to orthostatic hypotension |
| 12180246 | 2002 | Review | Clinics in Geriatric Medicine | Orthostatic hypotension in elderly patients: evaluation and management |
| 28092986 | 2017 | Review | The Annals of Pharmacotherapy | Efficacy and safety of pharmacological/non-pharmacological treatment of primary OH |
Safety Considerations
Please refer to the package insert for safety information. No key warnings, contraindications, or drug interaction data are currently available for this candidate — this is a blocking gap for safety review (see Next Steps).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The extension from established orthostatic-hypotension use to the broader “hypotensive disorder” category is mechanistically coherent and supported by multiple completed trials, including RCTs of midodrine itself in dialysis-associated, perioperative, and SCI-associated hypotension. However, the drug is not currently marketed in this jurisdiction, and safety labeling (warnings, contraindications) is entirely absent, which blocks a full safety evaluation.
To proceed, the following is needed:
- TFDA (or local) package insert with warnings and contraindications — currently a blocking data gap (DG001)
- Confirmed mechanism-of-action documentation from DrugBank (DG002)
- Drug interaction (DDI) data, particularly for cardiac conduction risk — none found in current query
- A registration/import pathway assessment, since the product holds zero local licenses
- No further work on the TxGNN top-ranked candidates (prion disease, faciodigitogenital syndrome, ADHD, monogenic obesity, developmental disorder, hypertelorism, sinoatrial node disease/block) — the evidence pack’s own rationale confirms these are model artifacts with no clinical or mechanistic support, and sinoatrial conduction disease in particular is a plausible relative contraindication (bradycardia risk) rather than an indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.